Scratching damages tight junctions through the Akt-claudin 1 axis in atopic dermatitis
- PMID: 32668051
- DOI: 10.1111/ced.14380
Scratching damages tight junctions through the Akt-claudin 1 axis in atopic dermatitis
Abstract
Background: Atopic dermatitis (AD) is a common, chronic, severely pruritic, eczematous skin disease that seriously deteriorates the quality of life of patients. Scratching is a cardinal symptom of AD. Although the vicious itch-scratch cycle continues and aggravates skin barrier dysfunction in AD, how scratching induces skin barrier dysfunction through tight junctions remains unclear.
Aim: To study the effect of scratching on tight junctions in the itch-scratch cycle.
Methods: Scratching behaviour and skin barrier dysfunction on the neck and back in an AD mouse model were assessed. The expression of tight junction proteins was compared between the neck and back mice, and the mechanisms underlying the involvement of Akt/CLDN1 pathways in this process were explored.
Results: We used oxazolone to induce AD on the neck or back of mice. There was significantly more scratching behaviour and more pronounced skin barrier dysfunction with the neck than with the back. Downregulation of claudin-1 (CLDN1) and upregulation of Akt phosphorylation in skin were well correlated with scratching behaviour in this AD model. Furthermore, SC79, an agonist of Akt phosphorylation, could downregulate CLDN1 expression in HaCaT cells. An antagonist of Akt phosphorylation (LY294002) was used to treat the AD mice; this treatment rescued CLDN1 expression through inhibiting Akt phosphorylation in skin, and importantly, also inhibited the scratching behaviour induced by AD.
Conclusion: The results reveal the underlying mechanism of tight junction damage promoted by scratching in the itch-scratch cycle of AD, and opens a new avenue to pruritus management in AD, through Akt antagonists.
© 2020 British Association of Dermatologists.
Similar articles
-
Osthole relieves skin damage and inhibits chronic itch through modulation of Akt/ZO-3 pathway in atopic dermatitis.Eur J Pharmacol. 2023 May 15;947:175649. doi: 10.1016/j.ejphar.2023.175649. Epub 2023 Mar 14. Eur J Pharmacol. 2023. PMID: 36921706
-
Dose-dependent role of claudin-1 in vivo in orchestrating features of atopic dermatitis.Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):E4061-8. doi: 10.1073/pnas.1525474113. Epub 2016 Jun 24. Proc Natl Acad Sci U S A. 2016. PMID: 27342862 Free PMC article.
-
Bortezomib, a proteasome inhibitor, alleviates atopic dermatitis by increasing claudin 1 protein expression.Biochem Biophys Res Commun. 2017 Nov 4;493(1):744-750. doi: 10.1016/j.bbrc.2017.08.120. Epub 2017 Aug 30. Biochem Biophys Res Commun. 2017. PMID: 28859979
-
Interleukin-33 in atopic dermatitis.J Dermatol Sci. 2019 Oct;96(1):2-7. doi: 10.1016/j.jdermsci.2019.08.006. Epub 2019 Aug 19. J Dermatol Sci. 2019. PMID: 31455506 Review.
-
Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.Allergy. 2018 Jan;73(1):29-36. doi: 10.1111/all.13239. Epub 2017 Jul 20. Allergy. 2018. PMID: 28670717 Review.
Cited by
-
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.JID Innov. 2022 Apr 26;2(5):100131. doi: 10.1016/j.xjidi.2022.100131. eCollection 2022 Sep. JID Innov. 2022. PMID: 36059592 Free PMC article. Review.
-
MRGPRX2 antagonist GE1111 attenuated DNFB-induced atopic dermatitis in mice by reducing inflammatory cytokines and restoring skin integrity.Front Immunol. 2024 May 16;15:1406438. doi: 10.3389/fimmu.2024.1406438. eCollection 2024. Front Immunol. 2024. PMID: 38817611 Free PMC article.
-
20-HETE mediated TRPV1 activation drives allokinesis via MrgprA3+ neurons in chronic dermatitis.Theranostics. 2024 Feb 4;14(4):1615-1630. doi: 10.7150/thno.85214. eCollection 2024. Theranostics. 2024. PMID: 38389848 Free PMC article.
-
The Role of Tight Junctions in Atopic Dermatitis: A Systematic Review.J Clin Med. 2023 Feb 15;12(4):1538. doi: 10.3390/jcm12041538. J Clin Med. 2023. PMID: 36836073 Free PMC article. Review.
-
The Protective Role of L-Cysteine in the Regulation of Blood-Testis Barrier Functions-A Brief Review.Genes (Basel). 2024 Sep 12;15(9):1201. doi: 10.3390/genes15091201. Genes (Basel). 2024. PMID: 39336792 Free PMC article. Review.
References
-
- Schmitt J, Apfelbacher C, Spuls PI et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol 2015; 135: 24-30.
-
- Simpson EL, Bruin-Weller M, Flohr C et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol 2017; 77: 623-33.
-
- Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int 2018; 67: 3-11.
-
- Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol 2018; 19: 319-32.
-
- Takeuchi S, Yasukawa F, Furue M, Katz SI. Collared mice: a model to assess the effects of scratching. J Dermatol Sci 2010; 57: 44-50.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials